Fulvestrant Clinical Trials

• A Comparison of the Efficacy and Tolerability of Fulvestrant (FASLODEX™) in Women with Breast Cancer
  ClinicalTrials.gov Identifier: NCT00099437 - Active, not recruiting
  Breast Cancer
  
• Enzastaurin Plus Fulvestrant vs. Placebo Plus Fulvestrant in Breast Cancer
  ClinicalTrials.gov Identifier: NCT00451555 - Recruiting
  Breast Neoplasms
  
• A Pilot Clinical Trial to Evaluate the Biological Activity of Fulvestrant in Breast Ductal Carcinoma in Situ (DCIS)
  ClinicalTrials.gov Identifier: NCT00183963 - Not yet recruiting
  Breast Carcinoma
  
• Fulvestrant or Tamoxifen in Treating Postmenopausal Women Who Are Undergoing Surgery for Ductal Carcinoma in Situ of the Breast
  ClinicalTrials.gov Identifier: NCT00126464 - Active, not recruiting
  intraductal breast carcinoma; breast cancer in situ
  
• Anastrozole and Gefitinib Compared With Fulvestrant and Gefitinib in Treating Postmenopausal Women With Recurrent or Metastatic Breast Cancer
  ClinicalTrials.gov Identifier: NCT00057941 - Active, not recruiting
  recurrent breast cancer; stage IV breast cancer
  
• Anastrozole With or Without Fulvestrant as First-Line Therapy in Treating Postmenopausal Women With Metastatic Breast Cancer
  ClinicalTrials.gov Identifier: NCT00075764 - Recruiting
  stage IV breast cancer; recurrent breast cancer
  
• Tipifarnib and Fulvestrant as Second-Line Therapy in Treating Postmenopausal Women With Hormone Receptor-Positive Inoperable Locally Advanced or Metastatic Breast Cancer With Progressive Disease After Previous First-Line Endocrine Therapy
  ClinicalTrials.gov Identifier: NCT00082810 - Active, not recruiting
  recurrent breast cancer; stage IIIB breast cancer; stage IIIC breast cancer; stage IV breast cancer
  
• Fulvestrant in Treating Patients With Recurrent, Persistent, or Metastatic Endometrial Cancer
  ClinicalTrials.gov Identifier: NCT00006903 - Recruiting
  stage IV endometrial cancer; recurrent endometrial cancer
  
• Fulvestrant and/or Trastuzumab in Treating Postmenopausal Women With Stage IV Breast Cancer
  ClinicalTrials.gov Identifier: NCT00138125 - Recruiting
  stage IV breast cancer; recurrent breast cancer
  
• Gefitinib With or Without Fulvestrant in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer
  ClinicalTrials.gov Identifier: NCT00100854 - Active, not recruiting
  stage IIIB non-small cell lung cancer; stage IV non-small cell lung cancer; recurrent non-small cell lung cancer
  
• Fulvestrant in Treating Patients With Advanced Prostate Cancer
  ClinicalTrials.gov Identifier: NCT00244998 - Active, not recruiting
  Prostate Cancer
  
• @FAME - Anastrozole and Fulvestrant Compared to Anastrozole as Adjuvant Treatment of Postmenopausal Patients With Breast Cancer
  ClinicalTrials.gov Identifier: NCT00357110 - Active, not recruiting
  Breast Cancer
  
• FINDER I - A Clinical Trial to Compare Efficacy and Tolerability of Fulvestrant 250mg, 250mg (Plus 250mg Loading Regimen) and 500mg
  ClinicalTrials.gov Identifier: NCT00305448 - Active, not recruiting
  Advanced Breast Cancer; Metastatic Breast Cancer
  
• A Clinical Trial to Compare Efficacy and Tolerability of Faslodex With Arimidex in Patients With Advanced Breast Cancer
  ClinicalTrials.gov Identifier: NCT00274469 - Active, not recruiting
  Metastatic Breast Cancer
  
• FACT - Anastrozole Monotherapy Versus Maximal Oestrogen Blockade With Anastrozole and Fulvestrant Combination Therapy
  ClinicalTrials.gov Identifier: NCT00256698 - Recruiting
  Breast Cancer
  
• FASLODEX and AROMASIN in Hormone Receptor Positive Postmenopausal Women with Advanced Breast Cancer
  ClinicalTrials.gov Identifier: NCT00065325 - Active, not recruiting
  Breast Neoplasms; Metastases, Neoplasm
  
• Fulvestrant With or Without Anastrozole or Exemestane Alone in Treating Postmenopausal Women With Locally Advanced or Metastatic Breast Cancer
  ClinicalTrials.gov Identifier: NCT00253422 - Recruiting
  Breast Cancer
  
• Exemestane in Combination With Fulvestrant in Postmenopausal Women With Hormone Sensitive Advanced Breast Cancer
  ClinicalTrials.gov Identifier: NCT00201864 - Recruiting
  Breast Cancer
  
• Fulvestrant (FASLODEX™) as a Treatment in Postmenopausal Women with Estrogen Receptor Positive Breast Cancer
  ClinicalTrials.gov Identifier: NCT00093002 - Completed
  Breast Cancer
  
• Fulvestrant in Treating Patients With Recurrent Prostate Cancer
  ClinicalTrials.gov Identifier: NCT00217464 - Recruiting
  Prostate Cancer
  
• Fulvestrant for the Treatment of Recurrent or Metastatic Endometrial Carcinoma.
  ClinicalTrials.gov Identifier: NCT00334295 - Recruiting
  Endometrial Carcinoma
  
• Bevacizumab Given With Either Anastrozole or Fulvestrant With Trastuzumab for Postmenopausal Metastatic Breast Cancer
  ClinicalTrials.gov Identifier: NCT00405938 - Recruiting
  Breast Cancer; Breast Neoplasms
  
• Phase II Trial of Capecitabine Plus Fulvestrant in First Line Treatment of Hormone Receptor Positive Metastatic Breast Cancer
  ClinicalTrials.gov Identifier: NCT00534417 - Recruiting
  Metastatic Breast Cancer
  
• Fulvestrant With or Without Lapatinib in Treating Postmenopausal Women With Stage III or Stage IV Breast Cancer That is Hormone Receptor-Positive and Expresses HER2
  ClinicalTrials.gov Identifier: NCT00390455 - Recruiting
  Breast Cancer
  
• Fulvestrant in Hormone Refractory Prostate Cancer
  ClinicalTrials.gov Identifier: NCT00476645 - Recruiting
  Prostate Cancer
  
• FINDER II - A Clinical Trial to Compare Efficacy and Tolerability of Fulvestrant 250mg, 250mg Plus 250mg Loading Regimen and 500mg
  ClinicalTrials.gov Identifier: NCT00313170 - Recruiting
  Advanced Breast Cancer; Metastatic Breast Cancer
  
• Fulvestrant (Faslodex) + Anastrozol (Arimidex) vs Anastrozol
  ClinicalTrials.gov Identifier: NCT00543127 - Not yet recruiting
  Breast Cancer
  
• Randomized, Double Blind Multicenter Phase II Study of Time to Progression on Fulvestrant in Combination With Erlotinib or Placebo in Hormone Receptor-Positive Metastatic Breast Cancer (MBC) Subjects Who Progressed on First Line Hormonal Therapy
  ClinicalTrials.gov Identifier: NCT00570258 - Recruiting
  Metastatic Breast Cancer
  
• AZD2171 in Addition to Fulvestrant in Patients With Advanced Breast Cancer
  ClinicalTrials.gov Identifier: NCT00454805 - Recruiting
  Advanced Breast Cancer
  
• Phase 2 Study of Combined Fulvestrant and RAD001 in Advanced/Metastatic Breast Cancer After Aromatase Inhibitor Failure
  ClinicalTrials.gov Identifier: NCT00570921 - Not yet recruiting
  Breast Cancer
  
• ICI 182780 in Treating Women With Metastatic Breast Cancer
  ClinicalTrials.gov Identifier: NCT00012025 - Active, not recruiting
  stage IV breast cancer; recurrent breast cancer; stage IIIB breast cancer; stage IIIC breast cancer
  
• Fulvestrant in Premenopausal Women with Hormone Receptor-Positive Breast Cancer
  ClinicalTrials.gov Identifier: NCT00146601 - Completed
  Invasive Breast Cancer; Stage IV Breast Cancer; Hormone Receptor-Positive Breast Cancer
  
• Fulvestrant and Bevacizumab in Treating Patients With Metastatic Breast Cancer
  ClinicalTrials.gov Identifier: NCT00423917 - Suspended
  Breast Cancer
  
• ICI 182780 in Treating Women With Stage I or Stage II Primary Breast Cancer
  ClinicalTrials.gov Identifier: NCT00010153 - Completed
  stage I breast cancer; stage II breast cancer